LAS VEGAS, Nov. 12, 2009 (GLOBE NEWSWIRE) -- Skinvisible, Inc. (OTCBB:SKVI), a
pharmaceutical research and development company announced today that it has
successfully completed a new clinical study proving that its hand sanitizer
lotion DermSafe(R) kills/inactivates the H1N1 virus on humans. This in-vivo
study proves that DermSafe meets the criteria set-out by internationally
accepted study guidelines to show efficacy against the H1N1 "swine flu" virus.
The study, performed at the independent testing laboratory Bioscience
Laboratories, Inc., required that the subjects' finger pads be contaminated with
the H1N1 virus and then examined according to the American Society for Testing
and Materials (ASTM) Standards. The results of the study proved that DermSafe
killed the virus to the same detection level as 70% alcohol. In some countries,
this study allows Skinvisible to submit data for approval to include "Kills
H1N1" on the product label. This further confirms the efficacy of DermSafe as
previously announced in an in-vitro study conducted at Retroscreen Virology,
where DermSafe also achieved a 99.99% kill / inactivation of the H1N1 virus.
Furthermore, DermSafe was also successfully tested in an in-vivo bacterial hand
disinfection study using the European Standard Method. This study method is used
in a number of countries in Europe and also in Canada for approval in the
healthcare and food services industries. The results proved the efficacy of
DermSafe against bacteria on artificially contaminated hands as compared to the
reference product of 60% isopropanol, a typical alcohol used in hand sanitizers.
"We are very pleased with the clinical results DermSafe achieved in these two
studies," said Mr. Terry Howlett, President and CEO of Skinvisible. "This proves
that DermSafe is an effective alternative to alcohol, without the drying and
safety issues. It also represents an important milestone to accelerate our
license negotiations in various countries as these studies are required for
regulatory approval in some jurisdictions. We also expect these additional
studies will solidify and expedite further approvals globally."
DermSafe is formulated with Skinvisible's patented technology Invisicare(R), a
polymer delivery system that is proven to bind to skin and resist wash-off for
up to four hours, thereby providing continuous antimicrobial protection. The
active ingredient in DermSafe is chlorhexidine gluconate 4%, which has been
safely used in hospital surgery rooms worldwide for over fifty years as a
pre-surgical hand scrub.
About Invisicare
Invisicare is Skinvisible's patented polymer delivery system that offers
life-cycle management and unique enhancements for topically delivered products.
It is a combination of hydrophilic and hydrophobic polymers that hold active
ingredients on the skin for extended periods of time resisting both wash off and
perspiration. Invisicare can control the release of actives and reduce
irritation. It is non-occlusive and allows for normal skin respiration while
protecting against environmental irritants. www.invisicare.com
About Skinvisible Pharmaceuticals, Inc.
Skinvisible Pharmaceuticals is a research-and-development company whose primary
business objective is to license its proprietary formulations with Invisicare to
pharmaceutical and cosmeceutical companies as well as assisting companies in
enhancing their existing skin care products. Skinvisible receives a combination
of research and development fees, upfront license fees, and ongoing royalties
for the life of the Invisicare patent. Skinvisible's value also lies in its
ability to continually generate new IP on dermatology and medical products
formulated with Invisicare. www.skinvisible.com
Forward-Looking Statements: This press release contains 'forward looking'
statements within the meaning of Section 21A of the Securities Act of 1933, as
amended, and Section 21E of the Securities Exchange Act of 1934, as amended, and
are subject to the safe harbors created thereby. Such statements involve certain
risks and uncertainties associated with an emerging company. Actual results
could differ materially from those projected in the forward looking statements
as a result of risk factors discussed in Skinvisible, Inc. reports on file with
the U.S. Securities and Exchange Commission (including, but not limited to, a
report on Form 10K for the quarter ending June 30, 2009).
-0-
CONTACT: Skinvisible Pharmaceuticals, Inc.
Doreen McMorran
702-433-7154
info@skinvisible.com
